Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16077217 | 1.00 | KCNN4 (0.40) | KCNN4OPRL1ALDH1A1KIF11PDK2 | |
| SCHEMBL16026291 | 1.00 | KCNN4 (0.40) | KCNN4OPRL1ALDH1A1KIF11PDK2 | |
| SCHEMBL18105223 | 1.00 | KCNN4 (0.40) | KCNN4OPRL1ALDH1A1KIF11PDK2 | |
| SCHEMBL18707708 | 1.00 | KCNN4 (0.40) | KCNN4OPRL1ALDH1A1KIF11PDK2 | |
| SCHEMBL16026298 | 1.00 | KCNN4 (0.40) | KCNN4OPRL1ALDH1A1KIF11PDK2 | |
| SCHEMBL16041878 | 1.00 | KCNN4 (0.40) | KCNN4OPRL1ALDH1A1KIF11PDK2 | |
| SCHEMBL16042008 | 1.00 | KCNN4 (0.40) | KCNN4OPRL1ALDH1A1KIF11PDK2 | |
| SCHEMBL18707709 | 0.78 | KCNN4 (0.38) | KCNN4KIF11 | |
| SCHEMBL18104111 | 0.76 | HTR2C (0.33) | — | |
| SCHEMBL16077219 | 0.76 | HTR2C (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964644-B1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC (US) | 2018-12-26 | — | — | EP | disclosed |
| US-9611261-B2 | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160280695-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2016-09-29 | — | — | US | disclosed |
| US-20150252011-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC (US) | 2015-09-10 | — | — | US | disclosed |
| US-9085576-B2 | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140275058-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280695-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | KCNN4 1694/4885OPRL1 886/4885ALDH1A1 317/4885 |
| US-20140275058-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | KCNN4 1694/4885OPRL1 886/4885ALDH1A1 317/4885 |
| US-20150252011-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | KCNN4 1694/4885OPRL1 886/4885ALDH1A1 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.